What Is Retatrutide? Mechanism, Trial Evidence & UK Status

Retatrutide (developmental code LY3437943) is a synthetic peptide developed by Eli Lilly. The scientific literature describes it as a single molecule conjugated to a fatty-diacid moiety that simultaneously activates three metabolic receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This "triple agonist" design distinguishes it from GLP-1 mono-agonists such as semaglutide and GLP-1/GIP dual agonists such as tirzepatide.

Research use only. Material supplied as a research peptide is intended for in-vitro laboratory use. It is not a medicine and is not for human or veterinary consumption, administration, or therapeutic use.

In published research each receptor target is associated with a distinct effect:

• GLP-1 receptor — appetite signalling and slowed gastric emptying in study models.
• GIP receptor — insulin sensitivity and adipose-tissue modulation.
• Glucagon receptor — energy expenditure and fat oxidation.

Cell-culture data indicate retatrutide is somewhat less potent than the body's own ligands at the human glucagon and GLP-1 receptors and more potent at the GIP receptor. Reported pharmacokinetics describe an approximate six-day half-life in clinical study, which supported once-weekly subcutaneous administration in trial settings.

Retatrutide has progressed from Phase 2 into a Phase 3 programme. A Phase 2 obesity trial published in the New England Journal of Medicine (2023) reported notable body-weight and metabolic changes over 48 weeks at the highest doses studied. Eli Lilly's Phase 3 TRIUMPH programme comprises multiple trials; readouts reported in 2025–2026 described notable body-weight and metabolic changes at 68–80 weeks.

These outcomes come from controlled clinical trials conducted under medical supervision in defined patient populations. They are presented here for scientific context only — they are not claims about research-grade material and do not constitute medical advice.

As of 2026, retatrutide is not approved for any indication by any regulator worldwide, including the UK's MHRA, the European EMA, and the US FDA. It is an investigational compound that is accessible to humans only through authorised clinical trials. In April 2026 the MHRA publicly highlighted that unlicensed peptide products marketed with health claims are a regulatory concern. Material sold by research suppliers is therefore strictly research-use-only.

As a lyophilised (freeze-dried) peptide, retatrutide is typically kept frozen and reconstituted with bacteriostatic water for in-vitro work — see our reconstitution guide and storage guide. Because purity directly affects experimental reliability, identity and purity should be verified against a batch-matched Certificate of Analysis (COA) with HPLC and mass-spectrometry data.

Retatrutide is an investigational incretin triple agonist. By contrast, tesamorelin is a GHRH analogue that acts on an entirely different pathway (the growth-hormone axis). Browse the full metabolic research peptides range, or view retatrutide product details and COA.

Retatrutide is supplied strictly for in-vitro laboratory research use only. The peer-reviewed references below are provided for research context and do not imply that the compound is safe or effective for use in humans.

1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514-526. View source